厚生労働科学研究費補助金

がん臨床研究事業

切除不能胆道がんに対する治療法の確立に関する研究

平成２０年度　総括研究報告書

主任研究者　奥坂　拓志

平成２１（２００９）年３月

厚生労働科学研究費補助金

がん臨床研究事業

切除不能胆道がんに対する治療法の確立に関する研究

平成２０年度　総括研究報告書

主任研究者　奥坂　拓志

平成２１（２００９）年３月

目次

厚生労働科学研究費補助金（がん臨床研究事業）

総括研究報告書

切除不能胆道がんに対する治療法の確立に関する研究

主任研究者　奥坂　拓志　国立がんセンター中央病院　医長

研究要旨：胆道がんは我が国のがん死亡数の第6位を占めており、切除不能胆道がんは胆道がん患者の50%以上を占めている。新しい抗がん剤であるS-1は切除不能胆道がん患者に対する治療薬として用いることによりその治療成績の向上が期待されている。本研究では2つの臨床試験を実施しており、「進行胆道がんを対象としたゲムシタビン＋S-1併用療法とS-1単剤療法のランダム化第II相試験」は登録が順調に開始されており、「ゲムシタビン耐性胆道がんに対するS-1の第Ⅱ相試験」は登録が予定より早期に終了し、追跡調査が進められている。両試験とも比較的順調に進行しており、これらの成果は多くの患者に利益をもたらすことが期待される。

A．研究目的

切除不能胆道がん患者の予後はきわめて不良であり、その生存期間を向上するためには新しい有効な治療法の確立が必要であり、全国規模の比較試験が必須である。切除不能胆道がんに対して延命効果を証明した標準的な化学療法は確立していないが、現在国内外において、ゲムシタビン単独療法を対照群としたランダム化比較試験が進行中あるいは計画中であり、ゲムシタビン単独療法は事実上の標準治療法として位置づけられている。これらのランダム化比較試験のうち現在最も注目されているのが、ゲムシタビン単独療法とゲムシタビンとシスプラチンの併用療法との比較で、英国では第Ⅲ相試験が、本邦ではランダム化第Ⅱ相試験が進行中である。これらの試験の結果によっては、ゲムシタビンとシスプラチンの併用療法が標準治療となる可能性がある。一方、S-1は本邦で開発された新しい抗がん剤であり、切除不能胆道がんに対しても第Ⅱ相試験において良好な成績が示され適応拡大が申請され、平成19年8月に承認された。本研究では、最初にS-1単独療法とS-1とゲムシタビンの併用療法とのランダム化第Ⅱ相試験を実施し、より有用性が期待できるレジメンを慎重に選択し、続いて英国での第Ⅲ相試験後に明らかとなる標準治療法との第Ⅲ相試験を実施し、切除不能胆道がんに対する標準治療法を確立する。

さらにS-1は切除不能胆道がんに対する2次治療薬としての期待も大きく、その有効性と安全性を明らかにするため、「ゲムシタビン耐性胆道がんにおけるS-1の臨床第Ⅱ相試験」を実施する。

B．研究方法

（1）「進行胆道がんを対象としたゲムシタビン＋S-1併用療法とS-1単剤療法のランダム化第II相試験」について：

［研究形式］多施設共同のランダム化第Ⅱ相試験、プライマリーエンドポイントは1年生存割合。
［対象症例］切除不能胆道がんの未治療例、PS 0または1、骨髄・肝・腎などの主要臓器機能が保持され、十分な説明後に本人より文書で同意の得られた症例。
［症例の登録］JCOGデータセンターによる中央登録方式とする。
［治療内容］S-1単独療法群ではS-1をday 1-28に連日経口投与する。これを６週毎に原疾患の悪化または毒性のため中止するまで継続する。S-1とゲムシタビンの併用療法群ではゲムシタビンをday 1，8に静注投与し、S-1はday 1-14に連日経口投与する。これを３週毎に原疾患の悪化または毒性のため中止するまで継続する。
［予定症例数］症例数100例、症例集積期間2年を予定。
［研究の第三者的監視］JCOG（Japan Clinical Oncology Group）は厚生労働省がん研究助成金指定研究6班（20指-1～6）を中心に、同計画研究班6班および厚生労働科学研究費がん臨床研究事業22研究班、計33班の任意の集合体であり、JCOGに所属する研究班は共同で、Peer reviewと外部委員審査を併用した第三者的監視機構としての各種委員会を組織し、科学性と倫理性の確保に努めている。本研究も、JCOGのプロトコール審査委員会、効果・安全性評価委員会、監査委員会、などによる第三者的監視を受けることを通じて、科学性と倫理性の確保に努める。

（２）「ゲムシタビン耐性胆道がんに対するS-1の第Ⅱ相試験」について：
［研究形式］多施設共同の第Ⅱ相試験、プライマリーエンドポイントは奏効割合。
［対象症例］ゲムシタビン耐性胆道がん例、PS 0または1、骨髄・肝・腎などの主要臓器機能が保持され、十分な説明後に本人より文書で同意の得られた症例。
［症例の登録］本研究事務局による中央登録方式とする。
［治療内容］S-1をday 1-28に連日経口投与する。これを６週毎に原疾患の悪化または毒性のため中止するまで継続する。
［予定症例数］症例数40例、症例集積期間2年を予定。

倫理面への配慮
参加患者の安全性確保については、適格条件やプロトコール治療の中止変更規準を厳しく設けており、試験参加による不利益は最小化される。また、「臨床研究に関する倫理指針」およびヘルシンキ宣言などの国際的倫理原則に従い以下を遵守する。
1）研究実施計画書のIRB承認が得られた施設のみから患者登録を行う。
2）すべての患者について登録前に充分な説明と理解に基づく自発的同意を本人より文書で得る。
3）データの取り扱い上、患者氏名等直接個人が識別できる情報を用いず、かつデータベースのセキュリティを確保し、個人情報（プライバシー）保護を厳守する。

C．研究結果
（１）「進行胆道がんを対象としたゲムシタビン＋S-1併用療法とS-1単剤療法のランダム化第II相試験」について：
本試験をJCOG肝胆膵グループの第1号試験として実施するため、肝胆膵グループの組織づくり、参加施設への教育・啓蒙活動を実施した。本研究コンセプトが平成19年7月にJCOGプロトコールレビュー審査会において承認。9月にJCOG運営委員会において承認を得た。本研究事務局とJCOGデータセンターによりプロトコー

ル作成作業が進められ、平成20年9月に一次審査での承認、12月にJCOGプロトコール審査委員会審査承認を得た。ただちに各施設倫理審査委員会での審査申請を行い、平成21年2月4日より登録受付を開始した。3月27日現在10名の登録が行われており、予定（4例／月）を上回る速度で試験が進行中である。

2）「ゲムシタビン耐性胆道がんに対するS-1の第Ⅱ相試験」について：

平成19年6月に第1例目の登録を開始し、平成20年1月までに21例（うち1例不適格）の登録を得た。この時点でプロトコールで予定された中間解析が行われ、1例以上の奏効例が確認できたことからさらに登録が継続された。平成20年9月までに41例目が登録され、登録予定期間2年のところ1年3か月で登録を終了した。現在追跡調査を進めており平成21年9月に追跡終了し、最終結果を解析する予定である。これまでのところ試験中止とすべき重篤な有害反応の報告は得られていない。

D．考察

我が国における胆道がん死亡数は増加傾向にあり、悪性腫瘍死亡数の第６位となっている。切除不能胆道がんに対して延命効果を証明した標準的な化学療法は確立していないが、現在国内外において、ゲムシタビン単独療法を対照群としたランダム化比較試験が進行中あるいは計画中であり、ゲムシタビン単独療法は事実上の標準治療法として位置づけられている。しかしその治療成績は生存期間中央値がわずかに8～9か月程度ときわめて不良であり、より有効な治療法の開発が切望されている。最近、本邦で開発された経口抗がん剤であるS-1が切除不能胆道がんに対し優れた抗腫瘍効果を示すことが明らかにされ、2007年8月に胆道がんへの適応拡大が承認された。

日本は国際的に見て胆道がん患者が比較的多く、治療開発を積極的に行い、世界を牽引していく必要がある。また、日本で開発された薬剤であるS-1は胆道がんに対しても大いに期待されている薬剤であり、S-１を含む治療レジメンを評価することを目的とした本研究は国際的にも非常に重要であると考えられる。

E．結論

本研究の両試験とも順調に進行しており、これらの成果は多くの患者に利益をもたらすことが期待される。

F．健康危険情報

なし。

G．研究発表

１．論文発表

外国語論文

1) Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol, 62(5): 849-855, 2008.

2) Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M. Phase II study of cisplatin, epirubicin and cintinuous infusion of 5-flrorouracil in patients with advanced intrahepatic cholangiocellular carcinoma. Hepato-Gastroenterol, 55(85): 1380-1384, 2008

3) Hara T, Yamaguchi T, Sudo K, Nakamura K, Denda T, Ishihara T, Yokosuka O, Kouzu T. Expansion of metallic mesh

stent hole using a Soehendra stent retriever in multiple stenting of biliary hilar obstruction. Endoscopy, 40: E147-E148, 2008

4) Furuse J. Postoperative adjuvant treatments for biliary tract cancer. J Hepatobiliary Pancreat Surg, 15(5): 463-467, 2008.

5) Niwa T, Ueno M, Ohkawa S, Yoshida T, Doiuchi T, Ito K, Inoue T. Advanced pancreatic cancer; the us of the apparent diffusion coefficient to predict response to chemotherapy: Br J Radiol, 82: 28-34, 2009.

6) Yamao K, Bhatia V, Mizuno N, Sawaki A, Ishikawa H, Tajika M, Hoki N, Shimizu Y, Ashida R, Fukami N. EUS-guided choledochoduodenostomy for palliative biliary drainage in patients with malignant biliary obstruction: results of long-term follow-up. Endoscopy, 40(4): 340-342, 2008

7) Makino T, Fujitani K, Tsujinaka T, Hirao M, Kashiwazaki M, Nakamori S, Ikenaga M, Mishima H, Masuda N, Sawamura T . Role of percutaneous transhepatic biliary drainage in patients with obstructive jaundice caused by local recurrence of gastric cancer. Hepatogastroenterology, 55 (81): 54-57, 2008.

日本語論文

1) 上野秀樹、奥坂拓志. 胆道癌. 看護のための最新医学講座 第２版 第24巻腫瘍の臨床. 日野原重明他監修. 中山書店. 東京. p70-76, 2008.

2) 森実千種、奥坂拓志、小菅智男. 切除不能胆道癌や切除後の補助療法として確立されている化学療法はあるのでしょうか？ 19. 胆道癌の補助化学療法. 消化器癌の外科治療. 2. 肝・胆・膵 こんなときどうする Q&A. 上西紀夫、中尾昭公編集. 中外医学社. 東京. 2008年10月. pp. 138-141.

3) 古瀬純司. 胆道癌化学療法の現状と今後の展望. 胆道 22(1):86-93, 2008.

4) 古瀬純司. 肝内胆管癌-2008, up-to-date-. 化学療法による治療成績. 肝胆膵 57(1):135-142, 2008.

5) 古瀬純司. 国際共同臨床試験. 国際共同臨床試験の現状と課題. 肝・胆道・膵がん. 腫瘍内科 2(3):197-204, 2008.

6) 古瀬純司. 胆道癌に対する術前・術後補助療法. 臨床外科 63(13):1737-1745, 2008.

7) 古瀬純司. 胆道癌診療ガイドラインを学ぶ—最新のエビデンスとコンセンサス. 胆道癌の化学療法に関するエビデンスとコンセンサス. 外科 71(1):53-60, 2009.

8) 大川伸一. 局所進行膵癌に対する化学療法. 内科:102(4): 729-732, 2008.

9) 大川伸一. 膵・胆道癌に対する化学療法. 消化器がん化学療法 2008 市倉隆編集. 日本メディカルセンター. 東京. p231-237, 2008.

10) 沼田和司、杉森一哉、森本学、大西奈緒美、田中克明. 超音波up date: フローイメージングの新たなる展開 胆・膵. 臨床画像, 24(5): 34-38, 2008.

11) 朴 成和. 胆道癌治療の最前線－化学療法の立場から－. 胆道癌治療の最前線. 医学図書出版株式会社. 東京. 2008年. pp26-32.

２．学会発表

1) 奥坂拓志. 胆道癌化学療法の最近の知見. 第44回日本胆道学会学術集会. 2008年9月19-20日. 於：名古屋市. 胆道

22(3):293, 2008.

2) 古瀬純司. 胆道癌の診断と治療：最前線　胆道癌に対する化学療法の現状と今後の展望. 第44回日本胆道学会学術集会. 2008年9月20日. 名古屋市.

3) 大川伸一、上野誠、谷合央. 無作為化比較試験における胆道癌に対するGemcitabine/CDDP併用療法とGemcitabine単独療法の使用経験. 第47回日本癌治療学会　2008年10月31日. 於：名古屋市. 日本癌治療学会誌 43(2):471, 2008.

4) 沼田和司. 特別企画　領域横断　造影超音波の現況と展望. 膵腫瘍、胆嚢病変の造影超音波.　超音波学会関東地方会.　2008年10月25日. 東京.

5) 大西奈緒美、沼田和司、森本学、杉森一哉、田中克明. 膵腫瘍、胆嚢病変のSonazoid造影超音波. 日本超音波医学会. 2008年5月24日. 神戸国際会議場.

6) 沼田和司、杉森一哉、田中克明. ワークショップ　三次元造影超音波による胆膵疾患診断に対する有用性の検討. 画像医学会. 2008年2月23日.

7) 天野歩、沼田和司、杉森一哉. シンポジウム　胆膵画像診断の進歩 三次元造影超音波による胆膵疾患診断に対する有用性の検討. 第94回日本消化器病学会総会. 2008年5月9日. 福岡

8) 杉森一哉、小倉孝氏、斉藤恵子. パネルディスカッション　胆道ステントの適応と選択　切除不能悪性中下部胆管狭窄に対するcovered metallic stentの比較　～Covered Wallstent vs. Niti-S ConVi stent～　理想的なstentは？　2008年10月3日. 東京

9) 田宮朗裕、遠藤正浩、小野　哲、山本信之、今澤雅子、富田秀春、中島孝治、多久佳成、小島　隆嗣、山崎健太郎、安井博史、廣中秀一、福富　晃、小野澤祐輔、朴　成和. ゲムシタビンによる薬剤性間質性肺炎－膵臓癌・胆管癌患者での検討－. 第6回日本臨床腫瘍学会学術集会. 2008年3月20-21日. 於：福岡市

10) 中森正二、辻江正徳、宮本敦史、柏崎正樹、黒川幸典、安井昌義、池永雅一、平尾素宏、藤谷和正、三嶋秀行、辻仲利政 . 切除不能・再発胆道癌に対するTS-1先行ジェムザール併用化学療法の検討. 第20回日本肝胆膵外科学会・学術集会, 2008年5月28日－30日. 於：山形市.

11) 宮本敦史、中森正二、辻江正徳、黒川幸典、山村順、安井昌義、増田慎三、大宮英泰、池永雅一、宮崎道彦、平尾素宏、高見康二、藤谷和正、三嶋秀行、辻仲利政 . 胆嚢癌に対する外科的治療に関する検討. 第20回日本肝胆膵外科学会・学術集会, 2008年5月28日－30日. 於：山形市.

12) 中森正二、辻江正徳、宮本敦史、安井昌義、池永雅一、平尾素宏、藤谷和正、三嶋秀行、辻仲利政 . 胆・膵癌術後再発例に対するTS-1先行Gemcitabine併用化学療法. 第 63回日本消化器外科学会総会, 2008年7月16日－18日. 於：札幌市. 日本消化器外科学会雑誌, 41(7), 2008.

13) 中森正二、辻江正徳、宮本敦史、川村美貴、黒川幸典、安井昌義、池永雅一、平尾素宏、藤谷和正、多賀谷光正、三嶋秀行、辻仲利政 . TS-1 治療中に可逆性後部白質脳症症候群（RPLS）を発症した再発胆管癌の 1 例. 第 46 回日本癌治療学会総会, 2008 年 10 月 30 日－11 月 1 日. 於：名古屋市.

14) 井岡達也、中泉明彦、田中幸子. 切除不能の胆道癌に対するゲムシタビン＋Ｓ１併用化学療法（パラレルI相試験）第94回消化器病学会総会. 2008年5

月9日．於：福岡市．

15）灘野成人，浅木彰則，松原寛，池田宜央，那須淳一郎，堀伸一郎，仁科智裕，鳥巣真幹，梶原猛史，谷水正人，井口東郎．切除不能・再発胆道癌に対する塩酸ゲムシタビン療法の有用性．ワークショップ　1「消化器がん治療法の進歩（2)化学療法」．第90回日本消化器病学会四国支部例会．松山、2008年11月8日-9日．

H．知的財産権の出願・登録状況

1．特許取得

なし

2．実用新案登録

なし

3．その他

なし

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
上野秀樹、奥坂拓志.	胆道癌	日野原重明他監修	看護のための最新医学講座 第2版 第24巻腫瘍の臨床.	中山書店	東京	2008	70-76
森実千種、奥坂拓志、小菅智男.	切除不能胆道癌や切除後の補助療法として確立されている化学療法はあるのでしょうか?	上西紀夫、中尾昭公編集	9. 胆道癌の補助化学療法. 消化器癌の外科治療. 2. 肝・胆・膵 こんなときどうするQ&A.	中外医学社	東京	2008	138-141
大川伸一.	膵・胆道癌に対する化学療法.	市倉隆編集	消化器がん化学療法2008	日本ﾒﾃﾞｨｶﾙｾﾝﾀｰ	東京	2008	231-237
朴 成和.	胆道癌治療の最前線－化学療法の立場から－		胆道癌治療の最前線.	医学図書出版株式会社	東京	2008	26-32

雑誌

表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A.	S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.	Cancer Chemother Pharmacol	62(5)	849-855	2008
Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M.	Phase II study of cisplatin, epirubicin and cintinuous infusion of 5-flrorouracil in patients with advanced intrahepatic cholangiocellular carcinoma.	Hepato-Gastroenterol,	55 (85)	1380-1384	2008
Hara T, Yamaguchi T, Sudo K, Nakamura K, Denda T, Ishihara T, Yokosuka O, Kouzu T.	Expansion of metallic mesh stent hole using a Soehendra stent retriever in multiple stenting of biliary hilar obstruction.	Endoscopy	40	E147-E148	2008
Furuse J.	Postoperative adjuvant treatments for biliary tract cancer.	J Hepatobiliary Pancreat Surg	15(5)	463-467	2008

表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
Niwa T, Ueno M, Ohkawa S, Yoshida T, Doiuchi T, Ito K, Inoue T.	Advanced pancreatic cancer; the us of the apparent diffusion coefficient to predict response to chemotherapy	Br J Radiol	82	28-34	2009
Yamao K, Bhatia V, Mizuno N, Sawaki A, Ishikawa H, Tajika M, Hoki N, Shimizu Y, Ashida R, Fukami N.	EUS-guided choledochoduodenostomy for palliative biliary drainage in patients with malignant biliary obstruction: results of ling-term follow-up.	Endoscopy	40(4)	340-342	2008
Makino T, Fujitani K, Tsujinaka T, Hirao M, Kashiwazaki M, Nakamori S, Ikenaga M, Mishima H, Masuda N, Sawamura T.	Role of percutaneous transhepatic biliary drainage in patients with obstructive jaundice caused by local recurrence of gastric cancer.	Hepatogastroenterology	55 (81)	54-57	2008
古瀬純司.	胆道癌化学療法の現状と今後の展望.	胆道	22(1)	86-93	2008
古瀬純司.	肝内胆管癌-2008, up-to-date-. 化学療法による治療成績.	肝胆膵	57 (1)	135-142	2008
古瀬純司.	国際共同臨床試験. 国際共同臨床試験の現状と課題. 肝・胆道・膵がん.	腫瘍内科	2(3)	197-204	2008
古瀬純司.	胆道癌に対する術前・術後補助療法.	臨床外科	63 (13)	1737-1745	2008
古瀬純司.	胆道癌診療ガイドラインを学ぶ—最新のエビデンスとコンセンサス. 胆道癌の化学療法に関するエビデンスとコンセンサス.	外科	71 (1)	53-60	2009
大川伸一.	局所進行膵癌に対する化学療法.	内科	102 (4)	729-732	2008
沼田和司、杉森一哉、森本学、大西奈緒美、田中克明.	超音波up date: フローイメージングの新たなる展開 胆・膵.	臨床画像	24(5)	34-38	2008

厚生労働科学研究費補助金

がん臨床研究事業

切除不能胆道がんに対する治療法の確立に関する研究

平成２０年度　研究成果の刊行物・別刷

研究代表者　奥坂　拓志
研究分担者　宮川　宏之
浜本　康夫
藤井　博文
山口　研成
山口　武人
池田　公史
石井　浩
古瀬　純司
大川　伸一
田中　克明
朴　成和
山雄　健次
中森　正二
井岡　達也
井口　春郎
船越　顕博

Cancer Chemother Pharmacol (2008) 62:849–855
DOI 10.1007/s00280-007-0673-7

ORIGINAL ARTICLE

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

Junji Furuse · Takuji Okusaka · Narikazu Boku · Shinichi Ohkawa · Akira Sawaki · Toshikazu Masumoto · Akihiro Funakoshi

Received: 11 October 2007 / Accepted: 23 December 2007 / Published online: 23 January 2008

Abstract A pilot phase II study showed S-1 monotherapy to be safe and active against biliary tract cancer (BTC). We, therefore, conducted a multicenter phase II study to evaluate the antitumor effect and safety of S-1 in previously untreated patients with advanced BTC. Eligible patients had pathologically proven, unresectable adenocarcinoma with no prior chemotherapy or radiotherapy. Patients received S-1 orally at 80 mg/m^2 total daily dose divided b.i.d. for 28 days followed by 14 days of rest. Of the 41 enrolled patients, 40 were assessable. The primary tumor sites were as follows: gallbladder ($n = 20$), extrahepatic bile duct ($n = 15$), and the ampulla of Vater ($n = 5$). One patient (2.5%) achieved a complete response, 13 patients (32.5%) had partial responses, 17 patients (42.5%) had no change, 7 patients (17.5%) had progressive disease, and 2 patients (5.0%) were not evaluable. The overall objective response rate was 35.0%. The median overall survival (median OS) was 9.4 months, and the median time to progression was 3.7 months. Grade 3 or 4 toxicities included fatigue (7.5%), anorexia (7.5%) and T-Bil elevation (7.5%). Significant antitumor activity combined with a mild toxicity profile was observed. This monotherapy warrants further evaluation in a randomized study.

Keywords Biliary tract cancer · Chemotherapy · Phase II study · S-1

J. Furuse (✉)
Division of Hepatobiliary and Pancreatic Oncology,
National Cancer Center Hospital East, 6-5-1 Kashiwanoha,
Kashiwa-shi, Chiba 277-8577, Japan
e-mail: jfuruse@east.ncc.go.jp

T. Okusaka
Division of Hepatobiliary and Pancreatic Oncology,
National Cancer Center Hospital, Tokyo, Japan

N. Boku
Division of Gastrointestinal Oncology,
Shizuoka Cancer Center, Suntou-gun Shizuoka, Japan

S. Ohkawa
Division of Hepatobiliary and Pancreatic Medical Oncology,
Kanagawa Cancer Center, Yokohama, Japan

A. Sawaki
Department of Gastroenterology,
Aichi Cancer Center Hospital, Nagoya, Japan

T. Masumoto
Department of Internal Medicine,
National Shikoku Cancer Center, Matsuyama, Japan

A. Funakoshi
Department of Gastroenterology,
National Kyushu Cancer Center, Fukuoka, Japan

Introduction

Biliary tract cancer (BTC) is a common cause of death from cancer in Japan, with an estimated 16,000 deaths annually [21]. While surgery currently remains the only potentially curative treatment, the curative resection rates for gallbladder cancer range from 10 to 30% [8, 16]. Most patients are diagnosed at an unresectable advanced stage of disease because of the lack of characteristic early symptoms. Although systemic chemotherapy is indicated for patients with unresectable disease, no standard chemotherapy regimens have been established and prognosis remains extremely poor.

A previous report showed improved survival in patients with BTC who were treated with 5-fluorouracil (5-FU)-based chemotherapy, compared to best supportive care [7]. Efforts have been made to develop promising regimens for

the treatment of BTC using clinical trials examining systemic chemotherapy [9]. Among various reports on chemotherapy for BTC, fluoropyrimidines have been regarded to form the basis of chemotherapeutic strategies [3, 9, 25].

S-1 is an oral anticancer drug that consists of tegafur (FT) as a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo). The drug contains two biochemical modulators, CDHP and Oxo, that improve the tumor-selective toxicity of 5-FU [28]. CDHP is a competitive inhibitor of dihydropyrimidine dehydrogenase (DPD) that is involved in the degradation of 5-FU; it enables efficacious concentrations of 5-FU to be maintained in the plasma and tumor tissues. Oxo, a competitive inhibitor of orotate phosphoribosyltransferase (OPRT), inhibits the phosphorylation of 5-FU in the gastrointestinal tract, and reduces the serious gastrointestinal toxicity of 5-FU. S-1 has already been demonstrated to have potent antitumor activity against various solid tumors in clinical studies [4, 11, 22, 26, 27]. For example, the response rates for advanced gastric and pancreatic cancer in the phase II studies conducted in Japan were 49 and 38%, respectively [4, 27].

Regarding BTC, a pilot phase II study of S-1 showed promising results, with a 21% response rate (at least one measurable lesion) and a manageable toxicity profile in 19 patients with unresectable disease [31]. Therefore, we conducted a multicenter phase II study of S-1 monotherapy for the treatment of unresectable BTC to confirm the results of the pilot phase II study. The objectives of this study were to evaluate the response rate, toxicity, time-to-progression, and overall survival.

Materials and methods

Patient selection

The eligibility criteria for enrollment in the study were as follows: (1) histologically or cytologically confirmed adenocarcinoma of the biliary tract (extrahepatic bile duct, gallbladder, or ampulla of Vater); (2) capable of oral intake; (3) measurable disease on computed tomography (CT), magnetic resonance imaging (MRI) or X-ray film; (4) unresectable disease; (5) no history of prior anticancer treatment except resection; (6) age of 20–74 years; (7) a Karnofsky performance status (KPS) of 80–100 points; (8) adequate organ function–bone marrow function (hemoglobin $\geq$ 10.0 g/dL, leukocyte count 4,000–12,000/mm^3, neutrophil count $\geq$ 2,000/mm^3, platelet count $\geq$ 100,000/mm^3), renal function (serum creatinine concentration $\leq$ upper limit of normal), and hepatic function (serum bilirubin level $\leq$ 3 times upper limit of normal, serum aspartate transaminase (AST) and alanine transaminase (ALT) levels $\leq$2.5 times upper limit of normal); (9) a life expectancy $\geq$ 2 months; and (10) written informed consent from the patient. Patients were excluded if they had severe complications. The study was approved by the local institutional review boards at all participating centers.

Treatment plan

Patients received S-1 orally at 80 mg/m^2 total daily dose divided b.i.d. on days 1–28, followed by a 14-day recovery period. Specifically, during the treatment weeks, patients with a body-surface area of less than 1.25 m^2 received 80 mg daily (i.e. two doses of two 20 mg capsules, twice daily); those with a body-surface area of 1.25 m^2 or more but less than 1.5 m^2 received 100 mg daily (i.e. two doses of two 25 mg capsules, twice daily); and those with a body-surface area of 1.5 m^2 or more received 120 mg daily (i.e. two doses of three 20 mg capsules, twice daily). The drug was administered after the morning and evening meals. Chemotherapy was continued until evidence of progression, a request for withdrawal, or the development of unacceptable toxicity in the investigator's opinion. Compliance and drug accountability were thoroughly scrutinized: patients were asked to keep a diary tracking the intake of S-1 and other medications. S-1 was provided by Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan).

Evaluation of response and safety

All the patients who received at least one dose of the test drug were included in the response and toxicity evaluations. Tumor response was assessed by computed tomography (CT), magnetic resonance imaging (MRI) or X-ray films during each course and was evaluated according to the Japan Society for Cancer Therapy (JSCT) Criteria [15], which is basically similar to the World Health Organization Criteria. The response was secondarily assessed using the response evaluation criteria in solid tumors (RECIST) [29]. Objective responses were confirmed by a second evaluation performed at least 4 weeks later. Serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) levels were measured monthly using an immunoradiometric assay.

Assessments of the physical findings, blood biochemistry and urinalysis tests were conducted biweekly; vital signs were assessed as necessary. All adverse events were evaluated for severity according to the National Cancer Institute Common Toxicity Criteria, version 2.0. The duration and causal relationship to S-1 was first judged by the attending physicians.

An independent review committee reviewed the objective responses and the adverse events.

Statistical considerations

The primary efficacy parameter in this study was the overall response rate, as defined by the outcome based on tumor measurements. The other parameters were response duration, overall survival time and time-to-progression (TTP). Response duration was calculated from the date of the first documentation of a partial response to the date of progressive disease. The TTP was determined by the interval between the initiation of treatment and the date when disease progression (according to the JSCT criteria) was first documented. Overall survival was calculated from the first day of registration until death from any cause. The median OS and the median TTP were estimated using the Kaplan–Meier method. The threshold of the response rate was defined as 5%, and the expected rate was set at 20% because the response rate in the previous study was 21.1% [31]. If the true response rate of S-1 was 20%, a sample size of 40 would ensure that there was at least an 80% power, at a one-sided significance level of 2.5%, to reject the null hypothesis that the response rate was less than 5%. If objective responses were obtained in six or more of the 40 patients, the lower limit of the 95% confidence interval (95% C.I.) of the response rate would clear the 5% threshold.

Results

Patients

A total of 41 patients were recruited from 7 institutions between January and December 2004. S-1 was not administered in 1 patient because this patient's γ-GTP level increased to grade 4 prior to the start of treatment. The 40 patients who received S-1 treatment were assessed for toxicity, response, response duration, TTP and survival. The baseline patient characteristics are listed in Table 1. Most patients (95.0%) had a good KPS of 90–100 points. Eighteen patients (45.0%) had undergone a prior resection of the primary tumor with curative intent and were offered chemotherapy after the documentation of metastatic or local recurrence. Among the 18 patients who had undergone resection, 11 patients had extrahepatic bile duct carcinoma, 4 had gallbladder cancer, and 3 had ampulla of Vater cancer.

Table 1 Patient characteristics

	No. of patients (%)
Total	40
Sex	
Male	22 (55.0)
Female	18 (45.0)
Age (years)	
Median age (range)	59.5 (33–74)
Karnofsky performance status	
100	25 (62.5)
90	13 (32.5)
80	2 (5.0)
Location of primary tumor	
Extrahepatic bile duct	15 (37.5)
Gallbladder	20 (50.0)
Ampulla of Vater	5 (12.5)
Extent of disease	
Locally advanced	10 (25.0)
Metastatic	30 (75.0)
Metastatic sites	
Liver	26 (65.0)
Lymph node	24 (60.0)
Lung	2 (5.0)
Peritoneum	5 (12.5)
Ovary	1 (2.5)
Prior resection	
(+)	18 (45.0)
(−)	22 (55.0)
CA19-9 before treatment (U/mL)	
≤37	8 (20.0)
>37	32 (80.0)
CEA before treatment (ng/mL)	
≤5.0	22 (55.0)
>5.0	18 (45.0)

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen

Treatment

The initial dose of S-1 was 80 mg/day in 1 patient (2.5%), 100 mg/day in 18 (45.0%), and 120 mg/day in 21 (52.5%). A total of 160 cycles of S-1 chemotherapy were delivered, with a median of three cycles per patient (range, 1–24 cycles). Across all the cycles, patients received 91.4% of the initially prescribed chemotherapy. As of writing, 1 patient is continuing to receive the protocol therapy. Of the 39 patients who discontinued this treatment, 31 (79.5%) experienced disease progression, 6 (15.4%) refused further treatment because of adverse events such as an increase in serum bilirubin, anemia, rash, thrombocytopenia, edema and anorexia, one withdrew consent before the completion of the first course, and one discontinued the treatment based on the attending physician's advice after the patient had experienced a complete response for more than 2 years. After abandoning the S-1 treatment, 13 patients received second-line treatment: 10 patients had systemic chemotherapy with gemcitabine in 3 patients, cisplatin plus irinotecan

in 3, uracil/tegafur in 2, uracil/tegafur plus doxorubicin in 1, an investigational compound in 1; 2 patients had radiotherapy; and 1 patient had hepatic arterial chemoembolization. The other 25 patients received only the best supportive care, and the other patient was observed without anti-cancer treatment after CR.

Response and Survival

One patient achieved a complete response (CR), and 13 patients achieved partial responses (PRs), producing an overall objective response rate of 35.0% (95% C.I., 20.6–51.7%) according to the JSCT criteria. No change (NC) was noted in 17 patients (42.5%) and progressive disease (PD) was noted in 7 patients (17.5%). The remaining 2 patients were not evaluated because the radiographic assessment was not determined; one was treatment-related death and the other refused the further treatment. One patient evaluated as having a PR according to investigator assessments was assessed as having NC according to the independent review committee assessments, thus the response rate was 37.5% assessed by investigators, and the 35.0% according to the independent review committee, which corresponded reasonably well. The median response duration was 4.5 months. The response rate in patients with gallbladder cancer was higher than that of patients with other BTCs, but no significant difference in response rate was observed when the patients were grouped according to the location of their primary sites (Table 2). According to the RECIST criteria, there were 1 CR, 12 PRs, 18 stable disease (SD), 7 progression disease (PD) and 2 NE. Thus, the overall response rate was 32.5% (95%C.I., 18.6–49.1%). The criteria of JSCT describe the assessment of both the investigators and the independent review committee, while RECIST only concerns the latter.

The serum CA 19-9 level decreased by more than 50% in 13 (40.6%) of the 32 patients who had pretreatment levels of over the upper normal limit, and the serum CEA level decreased by more than 50% in 5 (27.8%) of the 18 patients who had pretreatment levels of over the upper normal limit. Among the 14 patients who experienced a reduction in their CA 19-9 level, CEA level or both, 9 patients (64.3%) had objective responses.

The median TTP was 3.7 months (95% C.I., 3.2–5.8 months; Fig. 1). The median OS was 9.4 months (95% C.I., 6.0–11.0 months), and the 1-year survival rate was 32.5% (Fig. 2). The median OS for patients with extrahepatic bile duct cancer was 9.3 months, while that for patients with gallbladder cancer was 8.1 months; while for patients with cancer in the ampulla of Vater, the median OS has not yet been reached (Fig. 3).

Table 2 Tumor response

	$n = 40$
Complete response	1 (2.5%)
Partial response	13 (32.5%)
Overall response	14 (35.0%) 95% CI, 20.6–51.7%
Extrahepatic bile duct	4/15 (26.7%)
Gallbladder	9/20 (45.0%)
Ampulla of Vater	1/5 (20.0%)
No change	17 (42.5%)
Progressive disease	7 (17.5%)
Not evaluable[a]	2 (5.0%)

[a] Radiographic assessment was not determined

Toxicity

Table 3 shows treatment-related adverse events. The most common hematological toxicities were anemia and



Fig. 1 Time to progression in 40 patients treated with S-1. The median time to progression was 3.7 months



Fig. 2 Overall survival in 40 patients treated with S-1. The median overall survival period was 9.4 months, and the 1-year survival rate was 32.5%



Fig. 3 Survival curves of patients with extrahepatic bile duct carcinoma ($n = 15$), gallbladder carcinoma ($n = 20$), or ampulla of Vater cancer ($n = 5$)

leukopenia (each over 50%), while the most common non-hematological toxicities were fatigue, an elevated serum bilirubin level, a reduced serum albumin level, a reduced serum total protein level, anorexia and an elevated AST level (each over 40%). Other major symptoms included nausea, stomatitis, and rash. Grade 3 or 4 toxicities were observed in 16 of the 40 patients (40%). The major Grade 3 or 4 toxicities were lymphopenia (17.5%), anemia (10.0%), fatigue (7.5%), anorexia (7.5%), and serum bilirubin elevation (7.5%). Five patients required S-1 dose reduction because of adverse events. One treatment-related death occurred prior to the completion of the first cycle. The patient had been treated for gallbladder cancer and abdominal lymph node metastases, including metastases of the paraaortic lymph nodes. Although the patient had a history of obstructive jaundice, the condition was resolved using percutaneous biliary drainage before enrollment in this study. Grade 3 anorexia and fatigue in addition to dehydration developed, and S-1 was discontinued on day 16 after the start of administration. Grade 4 leukopenia was observed on day 17, and renal dysfunction developed on the same day; the serum creatinine level was 1.7 mg/dL, and the serum urea nitrogen level was 106 mg/dL. Thereafter, septic shock and disseminated intravascular coagulation (DIC) occurred, and the patient died 20 days after the start of treatment.

Discussion

This multicenter phase II study was initiated to confirm the efficacy and safety of S-1 monotherapy in advanced BTC. The expected response rate was set at 20%, but a 35.0% response rate was achieved, according to the JSCT criteria.

Table 3 Treatment-related adverse events ($n = 40$): worst grade reported during the treatment period

Toxicity	Grade				Grades 1–4	Grades 3–4
	1	2	3	4		
Total	2	20	14	2	95.0%	40.0%
Hematological						
Leukopenia	17	3	1	1[a]	55.0%	5.0%
Neutropenia	12	4	2	0	45.0%	5.0%
Anemia	9	11	3	1	60.0%	10.0%
Lymphopenia	0	11	7	0	45.0%	17.5%
Thrombocytopenia	7	5	1	0	32.5%	2.5%
Non-hematological						
Nausea	8	4	1	0	32.5%	2.5%
Vomiting	6	2	2	0	25.0%	5.0%
Fatigue	13	5	3	0	52.5%	7.5%
Anorexia	8	6	3	0	42.5%	7.5%
Diarrhea	4	4	0	0	20.0%	0%
Stomatitis	9	3	0	0	30.0%	0%
Rash	6	7	0	0	32.5%	0%
T-Bil elevation	3	12	3	0	45.0%	7.5%
AST elevation	9	6	1	0	40.0%	2.5%
ALT elevation	4	5	1	0	25.0%	2.5%
ALB reduction	7	10	0	0	42.5%	0%
T-protein reduction	14	3	0	0	42.5%	0%
Sepsis	0	0	0	1[a]	2.5%	2.5%
DIC	0	0	0	1[a]	2.5%	2.5%

T-Bil serum total bilirubin; *AST* serum aspartate aminotransferase; *ALT* serum alanine aminotransferase; *ALB* serum albumin; *DIC* disseminated intravascular coagulation

[a] Death related to adverse events

The lower limit of the 95% C.I. was over 20% of the expected response rate. Additionally, this multicenter phase II study was designed so that the response could also be evaluated according to the RECIST criteria. Accordingly, 1 patient achieved a CR, and 12 patients achieved a PR, for a response rate of 32.5% (95% C.I., 18.6–49.1%). Although 1 patient who was evaluated as having a PR according to the JSCT criteria was assessed as having SD according to the RECIST, the 35.0% response rate according to the JSCT criteria and the 32.5% response rate according to the RECIST criteria corresponded reasonably well.

The use of other oral fluoropyrimidines, like uracil/tegafur and capecitabine, against BTC has also been investigated. Uracil/tegafur alone or uracil/tegafur plus leucovorin were reported to have objective responses of 5 and 0%, respectively, and more than 60% of the patients were evaluated as having progressive disease after treatment with these regimens [10, 19]. The responses to capecitabine, a new prodrug of fluorouracil, and a combination of capecitabine and cisplatin were 19 and 21%, respectively [12, 24].

Thus, S-1 monotherapy may have a stronger activity against BTC than other fluoropyrimidine-based regimens, with regard to tumor response.

S-1 has been reported to be generally well tolerated in clinical trials, including a phase II study for patients with BTC [4, 11, 22, 26, 27]. In the current study, the most common toxicities were anemia, leukopenia, fatigue and elevated serum bilirubin and AST levels. Grade 3 or 4 toxicities were observed in 40% patients; thus, S-1 is considered to be tolerable, with toxicity levels comparable to those seen in patients with other solid tumors who underwent S-1 therapy [11, 22, 26, 27]. However, one treatment-related death occurred in this series; this patient developed severe leukopenia, septic shock and DIC prior to the completion of the first cycle of S-1 therapy. DPD deficiencies have been observed in some patients, and a close correlation has been reported between DPD activity and severe toxicity profiles in patients treated with fluorouracil [32]. In the above patient, severe toxicities occurred soon after the start of treatment, and a DPD deficiency was suspected. The DPD activity was investigated in the case of treatment-related death, but the activity was within the normal range. Based on the above-mentioned investigations, we speculated that dehydration as a result of biliary drainage and anorexia deteriorated the patient's renal function, in turn causing the excretion of 5-FU to decrease and resulting in the development of severe toxicities.

The gastrointestinal toxicity of fluorouracil is caused by the phosphorylation of fluorouracil by OPRT. Oxo, which is included in S-1, inhibits OPRT in the gastrointestinal tract, thereby reducing gastrointestinal toxicity. Among the grade 3 or 4 toxicities that occurred in the present study, the incidences of nausea (2.5%), anorexia (7.5%), vomiting (5.0%), and diarrhea (0%) were relatively low. Patients with biliary cancer often have obstructive jaundice before treatment. In these patients, treatment of cancer is initiated after jaundice has been treated. In the present study, 9 patients had abnormal T-Bil at the time of enrollment. In only 3 of the 9 patients, a treatment-emergent increase was considered to be an adverse drug reaction. However, it should be kept in mind that the incidence of T-Bil elevation was 45.0%. Although S-1 should be carefully administered to patients with external biliary drainage, it can be used in an outpatient setting with only minor toxicities, because of its safety, and this enhances its convenience.

In the current study, the median OS was 9.4 months, which was similar to the median OS of 8.3 months reported in the pilot phase II study on S-1. Recently, gemcitabine has shown promise as a new agent for the treatment of BTCs. In phase II trials, gemcitabine as a single agent achieved good responses of between 13 and 36% [6, 17, 23]. Moreover, gemcitabine-based combination regimens are reported to have response rates of more than 30% [1, 2, 13, 14]. In particular, a combination of gemcitabine and capecitabine achieved a 31% response rate and a median OS of 14.0 months. Combination regimens consisting of gemcitabine and S-1 have also been reported as promising in patients with advanced pancreatic cancer [30]. Based on these results, the combination of gemcitabine and S-1 should also be investigated for the treatment of BTC.

Various regimens, including combination chemotherapy regimens incorporating gemcitabine and the S-1 monotherapy reported in this study, have achieved encoureging response rates of 30% or more, but the median OS have varied from 4.6 to 15.4 months [1, 2, 13, 14]. Thus, there is variation in the survival period, despite of the high response rate. All of these trials, including the current study, consisted of a small number of patients (less than 50); thus the limited size of these series may account for the above variety. Survival can be affected by various factors, such as performance status and the site of the disease. Regarding the site of the disease, the median OS of patients with gallbladder cancer has been reported to be significantly shorter than that of patients with intrahepatic or extrahepatic bile duct carcinoma [5, 13]. A phase II study of gemcitabine plus cisplatin, reported by Doval et al., showed that the median OS was very short (20 weeks), although the response rate was relatively high at 36.6% [2]. The patients in Doval's study were limited to those with gallbladder cancer. The present study excluded patients with intarahepatic bile duct carcinoma because it is classified as a primary liver cancer, not a BTC, in the Japanese liver cancer and BTC guidelines [20, 18]. In the current study, no difference in survival was observed between patients with gallbladder cancer and those with extrahepatic bile duct carcinoma, but the median OS for the patient subgroup with ampulla of Vater cancer has not yet been reached. Although many clinical trials of chemotherapy for BTC have been conducted, no standard chemotherapy that can clearly prolong survival has been identified. The survival benefit of chemotherapy should be evaluated in large randomized prospective comparative studies that take the site of the biliary tumor and the performance status into consideration in the stratification strategy.

In conclusion, S-1 monotherapy was generally well tolerated and showed promising activity against advanced BTC. Further investigation in randomized studies is warranted to confirm the efficacy of S-1 in patients with BTC, including those with intrahepatic bile duct carcinoma. A multicenter randomized phase II study between S-1 alone and the combination of gemcitabine and S-1 is currently being planned by the Japan Clinical Oncology Group (JCOG).

Acknowledgments We thank Drs. M. Kurihara, S. Matsuno, O. Ishikawa, C. Hamada and T. Taguchi for their kind advice, and Drs. H. Saisho, N. Moriyama and W. Koizumi for this extramural review. The authors are indebted to Professor J. Patrick Barron of the International Medical Communications Center of Tokyo Medical University

for his review of this manuscript. This study was supported by Taiho Pharmaceutical Co. Ltd.

Conflict of interest The study was supported by Taiho Pharmaceutical Co., Ltd. (Tokyo). For all authors, there is no potential conflict of interest, relevant to this article.

References

1. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15(9):1339–1343
2. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90(8):1516–1520
3. Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54(6):965–969
4. Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa S et al (2005) A phase II study of S-1 in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 23:16s (Abstract No: 4104)
5. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36(9):552–556
6. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C et al (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12(10):1403–1406
7. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7(6):593–600
8. Haskell CM (ed) (2001) Cancer treatment, 5th edn. WB Saunders Co, Philadelphia
9. Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34(7):977–986
10. Ikeda M, Okusaka T, Ueno H, Morizane C, Furuse J, Ishii H (2005) A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 35(8):439–443
11. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85(7):939–943
12. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH et al (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14(7):1115–1120
13. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10):2332–2338
14. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ (2004) Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15(5):770–774
15. Koyama Y (ed) (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101–130
16. Levin B (1999) Gallbladder carcinoma. Ann Oncol 10(Suppl 4):129–130
17. Lin MH, Chen JS, Chen HH, Su WC (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49(3):154–158
18. Makuuchi M (ed) (2000) The general rules for the clinical and pathological study of primary liver cancer November 2000, 4th edn. Kanehara, Tokyo
19. Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE et al (1999) Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17(1):97–101
20. Nagakawa T (ed) (2003) General rules for surgical and pathological studies on cancer of the biliary tract September 2003, 5th edn. Kanehara, Tokyo
21. Nomura K (ed) (2005) Cancer statistics in Japan 2005. Foundation for Promotion of Cancer Research (FPCR), Tokyo
22. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K et al (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83(2):141–145
23. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57(5):647–653
24. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA et al (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3):578–586
25. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I et al (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14(8):2311–2315
26. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S et al (2004) A phase II study of S-1 in patients with metastatic breast cancer—a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11(2):194–202
27. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34(11):1715–1720
28. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
30. Ueno H, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S et al (2007) A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. ASCO 2007 Gastrointestinal Cancers Symposium (Abstract No: 148)
31. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10):1769–1774
32. van Kuilenburg AB, De Abreu RA, van Gennip AH (2003) Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40(Pt 1):41–45

Original Paper

Phase II Study of Cisplatin, Epirubicin and Continuous Infusion of 5-Fluorouracil in Patients with Advanced Intrahepatic Cholangiocellular Carcinoma (ICC)

Yoriko Takezako, Takuji Okusaka, Hideki Ueno, Masafumi Ikeda
Chigusa Morizane, Mina Najima
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Corresponding Author: Takuji Okusaka MD, PhD, Hepatobiliary and Pancreatic Oncology Division
National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Tel: +81 3 3542 2511, Fax: +81 3 3542 3815, E-mail: tokusaka@ncc.go.jp

KEY WORDS:
Cisplatin; Epirubicin; 5-Fluorouracil; Chemotherapy; Intrahepatic cholangiocellular carcinoma

ABBREVIATIONS:
5-Fluorouracil (5FU); Intrahepatic Cholangiocellular Carcinoma (ICC); Computed Tomography (CT); Biliary Tract Cancer (BTC); ECOG: Eastern Cooperative Oncology Group; Intravenous (IV)

ABSTRACT

Background/Aims: To clarify the efficacy and toxicity of cisplatin, epirubicin, and continuous infusion of 5-FU (CEF therapy) in patients with advanced intrahepatic cholangiocellular carcinoma (ICC).

Methodology: Chemo-naïve patients with advanced ICC were treated with cisplatin at 80mg/m² and epirubicin at 50mg/m² on day 1, and continuous infusion of 5-FU at 500mg/m²/day on days 1 through 5. If there was no evidence of tumor progression or unacceptable toxicity, the treatment was repeated every 4 weeks, up to a maximum of 6 courses.

Results: Thirty-nine patients were enrolled in this study. The median number of courses was 2 (range, 1-6). A partial response was obtained in 4 patients (10%) with a median duration of 2.3 months. Twenty-seven patients (69%) showed no change, and 7 patients (18%) had progressive disease. The median survival time was 9.1 months and the 1-year survival rate was 23%. The progression-free survival time was 5.1 months. Grade 3 to 4 adverse effects were leukocytopenia (51%), neutropenia (74%), thrombocytopenia (23%), and nausea/vomiting (10%). Most of the toxicities were reversible, but 2 patients died of neutropenic sepsis.

Conclusions: CEF therapy has marginal antitumor activity against advanced ICC, although hematological toxicity is the major and most frequent toxicity.

INTRODUCTION

Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy accounting for approximately 3.3% of primary malignant liver tumor in Japan (1). ICC is difficult to diagnose, with most patients surgically unresectable at the time of diagnosis. Moreover, even for those who undergo surgical resection, the risk of recurrence is exceedingly high, and the overall prognosis remains unsatisfactory. To improve the prognosis of patients with this disease, effective chemotherapy is essential, but standard chemotherapy for ICC has not been established. Furthermore, few disease-oriented studies of chemotherapy for ICC have been reported because of the low incidence of this disease.

The authors of the present study previously reported that cisplatin did not appear active as a single agent in treating patients with biliary tract cancer (BTC) including ICC; the response rate of this agent was only 8% (1/13), but a 50% or more reduction in the CEA level was obtained in 31% of patients (3). The activity of cisplatin is potentiated by certain other anticancer agents such as 5-FU (4,5). In addition, anthracyclines may enhance the cytotoxicity afforded by combining cisplatin and 5-FU (6). In fact, continuous infusion of 5-FU with cisplatin and epirubicin has been reported to be an active regimen in the management of gastrointestinal cancers such as gastroesophageal cancer (7-10). However, it appears that this combined treatment has not been evaluated in patients with ICC. Therefore, in this phase II study, the efficacy and toxicity of cisplatin, epirubicin, and continuous infusion of 5-FU (CEF therapy) in patients with unresectable ICC, was investigated.

METHODOLOGY

Patients

Patients eligible for this study had histologically confirmed unresectable advanced intrahepatic cholangiocarcinoma for which they had not had prior irradiation or chemotherapy. Each patient was required to meet the following eligibility criteria: an ECOG performance status (PS) of 0-2; 15-75 years of age; at least 1 bidimensionally measurable tumor; estimated life expectancy ≥8 weeks after study entry; adequate renal function (normal serum creatinine and blood urea nitrogen levels); adequate liver func-

Hepato-Gastroenterology 2008; 55:1380-1384